Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Ulinastatin) II
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Acute Aortic Syndrome (AAS) is a common feature of acute aortic wall events, including aortic
dissection, intramural hematoma, aortic ulceration and aortic trauma, and occurs in up to 35
cases per 100,000 cases per year between the ages of 65 and 75 years. Ulinastatin has
antiinflammatory activity and suppresses the infiltration of neutrophils and the release of
elastase and chemical mediators from neutrophils. Recent studies have shown that ulinastatin
may be cytoprotective against ischemia-reperfusion injury in the liver, kidney, heart, and
lung. The authors aim to examine the association between decreased release of inflammatory
response to urinary trypsin inhibitor treatment and decreased myocardial and lung injury
after acute aortic syndrome surgery.